Valdoxan
(agomelatine)Phase 3Small molecule
NovartisAgomelatine is used to treat depression by helping to restore normal sleep-wake cycles and improve mood. It works differently than many other antidepressants by acting on melatonin receptors in the brain.[1] Valdoxan is currently being investigated across 2 indications[3], with its most advanced program in Phase 3.[1]
Valdoxan is one of 59 small molecule programs targeting Fibromyalgia. It is currently in Phase 3.
2
Indications
19
Total Trials
1
Active Trials
58
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
42 competitors in Fibromyalgia
#DrugCompanyPhaseTrials
1Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Savella
AbbVieApproved
Cymbalta
Jazz PharmaceuticalsApproved
Elavil
AstraZenecaApproved
Keppra
UCBApproved
Emgality
Eli LillyApproved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Revia
TevaApproved
Xylocaine
MMEDRx USA, Inc.
Approved
Lunesta
Akero TherapeuticsApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Major Depressive Disorder8 trials
Show 5 more trials
Schizophrenia2 trials
Adolescent1 trial
Double-blind1 trial
A Double-blind, Placebo-controlled Study of Antidepressant Augmentation With Agomelatine
Completed·—·Phase 4·NCT04589143·137 enrolled
6 more indications
Depressed1 trial
Major Depression1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for agomelatine. EMBL-EBI & Wellcome Sanger Institute.
- [4]